ONC (US)

The White House’s biopharma tariffs announced last week [Fact Sheet] strike us as an aggressive effort to secure additional onshoring and most favored nation (MFN) pricing agreements with manufacturers, but the clock is likely ticking…

CMS’s mandatory Medicare Part D (here) / Part B (here) international drug pricing model proposals released Friday suggest that – besides an ostensible reprieve from as yet unrealized tariffs – recent drug manufacturer “deals” with…